BR112014002576B1 - Fragmento fab de anticorpo anti-ngf humano, método para produzir o mesmo e vetor de expressão compreendendo um polinucleotídeo que codifica o dito fragmento fab' - Google Patents

Fragmento fab de anticorpo anti-ngf humano, método para produzir o mesmo e vetor de expressão compreendendo um polinucleotídeo que codifica o dito fragmento fab' Download PDF

Info

Publication number
BR112014002576B1
BR112014002576B1 BR112014002576-2A BR112014002576A BR112014002576B1 BR 112014002576 B1 BR112014002576 B1 BR 112014002576B1 BR 112014002576 A BR112014002576 A BR 112014002576A BR 112014002576 B1 BR112014002576 B1 BR 112014002576B1
Authority
BR
Brazil
Prior art keywords
fab
fragment
antibody
human
ngf
Prior art date
Application number
BR112014002576-2A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014002576A2 (pt
Inventor
Masazumi Kamohara
Hirotsugu Tanaka
Yukari Koya
Jun Takasaki
Atsuo Yonezawa
Eiji Yoshimi
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of BR112014002576A2 publication Critical patent/BR112014002576A2/pt
Publication of BR112014002576B1 publication Critical patent/BR112014002576B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112014002576-2A 2011-08-11 2012-08-10 Fragmento fab de anticorpo anti-ngf humano, método para produzir o mesmo e vetor de expressão compreendendo um polinucleotídeo que codifica o dito fragmento fab' BR112014002576B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011-176209 2011-08-11
JP2011176209 2011-08-11
JP2011-269215 2011-12-08
JP2011269215 2011-12-08
PCT/JP2012/070433 WO2013022083A1 (ja) 2011-08-11 2012-08-10 新規抗ヒトｎｇｆ抗体

Publications (2)

Publication Number Publication Date
BR112014002576A2 BR112014002576A2 (pt) 2021-01-12
BR112014002576B1 true BR112014002576B1 (pt) 2022-08-23

Family

ID=47668585

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002576-2A BR112014002576B1 (pt) 2011-08-11 2012-08-10 Fragmento fab de anticorpo anti-ngf humano, método para produzir o mesmo e vetor de expressão compreendendo um polinucleotídeo que codifica o dito fragmento fab'

Country Status (30)

Country Link
US (2) US8986952B2 (https=)
EP (1) EP2743348B1 (https=)
JP (1) JP5376095B2 (https=)
KR (1) KR101999867B1 (https=)
CN (1) CN103748222B (https=)
AR (1) AR087506A1 (https=)
AU (1) AU2012293161B2 (https=)
BR (1) BR112014002576B1 (https=)
CA (1) CA2841181C (https=)
CY (1) CY1119914T1 (https=)
DK (1) DK2743348T3 (https=)
EA (1) EA024292B1 (https=)
ES (1) ES2663968T3 (https=)
HR (1) HRP20180155T1 (https=)
HU (1) HUE036079T2 (https=)
IL (1) IL230797A (https=)
IN (1) IN2014CN00614A (https=)
LT (1) LT2743348T (https=)
ME (1) ME02944B (https=)
MX (1) MX351273B (https=)
NO (1) NO2743348T3 (https=)
PH (1) PH12014500001A1 (https=)
PL (1) PL2743348T3 (https=)
PT (1) PT2743348T (https=)
RS (1) RS56876B1 (https=)
SI (1) SI2743348T1 (https=)
SM (1) SMT201800166T1 (https=)
TW (1) TWI554519B (https=)
WO (1) WO2013022083A1 (https=)
ZA (1) ZA201400741B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
CA2986210C (en) * 2015-05-22 2022-04-26 Astellas Pharma Inc. Novel anti-human ngf antibody fab fragment
JPWO2017164349A1 (ja) * 2016-03-25 2019-02-07 アステラス製薬株式会社 ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物
CN114751982B (zh) * 2017-12-15 2023-06-23 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1994020632A1 (fr) 1993-03-11 1994-09-15 Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute Anticorps monoclonal dirige contre le vih
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1401498T3 (da) 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN102408483B (zh) 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
WO2006077441A1 (en) 2005-01-24 2006-07-27 Cambridge Antibody Technology Limited Specific binding members for ngf
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
BRPI0815370B8 (pt) 2007-08-10 2021-05-25 Regeneron Pharma anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica
RU2461551C2 (ru) 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
SG175436A1 (en) 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Also Published As

Publication number Publication date
AU2012293161B2 (en) 2017-04-27
EP2743348A4 (en) 2015-04-29
TW201319086A (zh) 2013-05-16
SI2743348T1 (en) 2018-04-30
IL230797A (en) 2017-06-29
CY1119914T1 (el) 2018-06-27
IN2014CN00614A (https=) 2015-04-03
EP2743348A1 (en) 2014-06-18
PH12014500001A1 (en) 2014-02-10
JP5376095B2 (ja) 2013-12-25
TWI554519B (zh) 2016-10-21
SMT201800166T1 (it) 2018-05-02
CA2841181A1 (en) 2013-02-14
ES2663968T3 (es) 2018-04-17
LT2743348T (lt) 2018-05-10
KR20140047116A (ko) 2014-04-21
MX351273B (es) 2017-10-06
CA2841181C (en) 2022-01-25
EA024292B1 (ru) 2016-09-30
KR101999867B1 (ko) 2019-07-12
HUE036079T2 (hu) 2018-06-28
BR112014002576A2 (pt) 2021-01-12
PL2743348T3 (pl) 2018-04-30
HRP20180155T1 (hr) 2018-03-23
ZA201400741B (en) 2014-11-26
AR087506A1 (es) 2014-03-26
NO2743348T3 (https=) 2018-06-09
US20150218265A1 (en) 2015-08-06
US8986952B2 (en) 2015-03-24
ME02944B (me) 2018-04-20
CN103748222A (zh) 2014-04-23
US20140155582A1 (en) 2014-06-05
WO2013022083A1 (ja) 2013-02-14
IL230797A0 (en) 2014-03-31
DK2743348T3 (en) 2018-02-26
AU2012293161A1 (en) 2014-02-06
JPWO2013022083A1 (ja) 2015-03-05
PT2743348T (pt) 2018-02-23
EA201490433A1 (ru) 2014-05-30
CN103748222B (zh) 2015-07-22
MX2014001627A (es) 2014-05-28
EP2743348B1 (en) 2018-01-10
RS56876B1 (sr) 2018-04-30

Similar Documents

Publication Publication Date Title
BR112014002576B1 (pt) Fragmento fab de anticorpo anti-ngf humano, método para produzir o mesmo e vetor de expressão compreendendo um polinucleotídeo que codifica o dito fragmento fab'
US9127055B2 (en) Method of treating pain with anti-human NGF antibody
ES2633810T3 (es) Proteínas de unión a antígeno humanas que se unen a beta-Klotho, receptores de FGF y complejos de los mismos
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
BR112021001201A2 (pt) anticorpo anti-tigit e uso do mesmo
TWI685502B (zh) 新穎抗人類Ｔｉｅ２抗體
EA015589B1 (ru) Антитела против миостатина и их применение
MX2010009185A (es) Anticuerpos dirigidos a la angiopoietina-1 y la angiopoietina-2 y uso de los mismos.
BRPI0915660A2 (pt) antagonistas específicos do receptor fgf-r4
BRPI0711796A2 (pt) anticorpos de bloqueio de função de integrinas anti-alfa5beta1 humanos e humanizados com imunogenicidade reduzida
BR112020009707A2 (pt) anticorpos para a-sinucleína e usos dos mesmos
ES2665851T3 (es) Nuevo anticuerpo anti-CTGF humano
BR112020015961A2 (pt) Inibidor de gremlin-1 para o tratamento de uma fratura óssea ou defeito ósseo
JP6700620B2 (ja) 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
JP6135161B2 (ja) 新規抗ヒトｎｇｆ抗体
BRPI0414174B1 (pt) Anticorpos ou fragmentos de ligação a antígeno do mesmo uso dos mesmos, polinucleotídeo, vetor, sistema de expressão, e composição farmacêutica.
BR112021005670A2 (pt) polipeptídeos tetraméricos de ligação a her2
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40092141A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
Hu et al. Generation of a mouse monoclonal antibody recognizing both the native and denatured forms of human VEGF
WO2016116578A1 (en) Multimeric compounds of a kringle domain from the hepatocyte growth factor / scatter factor (hgf/sf)
NZ624876A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/08/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2787 DE 04-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.